Melanoma Pipeline Market Research Report for H2 2015

PUNE, India, March 7, 2016 /PRNewswire/ --

ReportsnReports.com adds "Melanoma - Pipeline Review, H2 2015" to its store providing an overview of the Melanoma's therapeutic pipeline with comprehensive information on and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects.

Complete report on H2 2015 pipeline review of Melanoma with 174 market data tables and 17 figures, spread across 1508 pages is available at http://www.reportsnreports.com/reports/468283-melanoma-pipeline-review-h2-2015.html   

Companies discussed in this Melanoma Pipeline Review research report include AB Science SA, AbbVie Inc., ACF Pharmaceuticals, LLC, Adamis Pharmaceuticals Corporation, Adaptimmune Limited, Aduro BioTech, Inc., Advaxis, Inc., Aeterna Zentaris Inc., Affichem SA, Agalimmune Ltd, Agenus, Inc., Agilvax, Inc., AGV Discovery, SAS, AIMM Therapeutics B.V., Alethia Biotherapeutics Inc., Altor BioScience Corporation, Amgen Inc., Anavex Life Sciences Corp., Antigen Express, Inc., APEIRON Biologics AG, Aphios Corporation, APO-T B.V., Aposense Ltd., Applied Immune Technologies Ltd, Aptose Biosciences Inc., Arisaph Pharmaceuticals, Inc. , Array BioPharma Inc., Arrowhead Research Corporation, Astex Pharmaceuticals, Inc., AstraZeneca Plc, Aurigene Discovery Technologies Limited, Axelar AB, Azaya Therapeutics, Inc., Basilea Pharmaceutica AG, Bayer AG, BeiGene(Beijing) Co.,Ltd, Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Biogenomics Limited, BioLineRx, Ltd., Bioncotech Therapeutics S.L., Bionomics Limited, BioNTech AG, Bioo Therapeutics, Biovista Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Caladrius Biosciences, Inc., Can-Fite BioPharma Ltd., Cantargia AB, cCAM Biotherapeutics Ltd., CCRP Therapeutics GmbH, Cellceutix Corporation, Celldex Therapeutics, Inc., Celyad SA, Champions Oncology, Inc., Cipher Pharmaceuticals Inc., Cornerstone Pharmaceuticals, Inc., Cytune Pharma SAS, CyTuVax B.V., CZ BioMed Corp, Daiichi Sankyo Company, Limited, Deciphera Pharmaceuticals, LLC, Delcath Systems, Inc., DermaXon, LLC, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L., DNA Therapeutics S.A., DormaTarg, Inc., Dynavax Technologies Corporation, EcoBiotics Limited, Egenix, Inc., Eisai Co., Ltd., Eli Lilly and Company, Ensol Biosciences Inc., EntreChem, S.L., Erytech Pharma SA, F. Hoffmann-La Roche Ltd., FAES Farma SA, FirstString Research, Inc., Five Prime Therapeutics, Inc., Formune S.L., Galapagos NV, Galectin Therapeutics, Inc., Galileo Research s.r.l., Genelux Corporation, Genzyme Corporation, GlaxoSmithKline Plc, Gradalis Inc., Hadasit Medical Research Services & Development Ltd, Hanmi Pharmaceuticals, Co. Ltd., HEC Pharm Co., Ltd., Histogen, Inc., Horizon Pharma Plc, Idera Pharmaceuticals, Inc., Ignyta, Inc., Immodulon Therapeutics Ltd., Immune Design Corp., Immune Response BioPharma, Inc., ImmunGene, Inc., ImmunNovative Developments SL, Immunocore Limited, ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomic Therapeutics, Inc., Immunophotonics Inc, ImmuRx, Inc., IMPACT Therapeutics, Inc., Imugene Limited, Incyte Corporation and Inovio Pharmaceuticals, Inc.

Order a copy of the melanoma pipeline H2 2015 review market research report @ http://www.reportsnreports.com/Purchase.aspx?name=468283  

The report also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Another newly published market research report titled EpiCast Report: Melanoma - Epidemiology Forecast to 2023 provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma of the skin, segmented by age (in 10-year age groups, beginning at 20 years and ending at =80 years), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] stages I, II, III, and IV). The forecast also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases and the five-year diagnosed prevalent cases segmented by genetic aberrations (BRAF and c-KIT) in these markets. EpiCast Report: Melanoma market research report of 51 pages is available at http://www.reportsnreports.com/reports/401538-epicast-report-melanoma-epidemiology-forecast-to-2023.html   

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/   

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com